September 2019

India has joined the Global Antimicrobial Resistance (AMR) Research and Development (R&D) Hub as a new member. This was announced by the Department of Biotechnology, Ministry of Science & Technology in New Delhi.

India has joined the Global Antimicrobial Resistance (AMR) Research and Development (R&D) Hub as a new member. This was announced by the Department of Biotechnology, Ministry of Science & Technology in New Delhi. This expands the global partnership working to address challenges and improve coordination and collaboration in global AMR R&D to 16 countries, the European Commission, two philanthropic foundations and four international organisations (as observers).

To spur innovation to meet the challenges of complex care management for people with Alzheimer’s disease and related dementias (AD/ADRD) and their families, the National Institute on Aging (NIA), part of the National Institutes of Health, has funded a new effort designed to test care interventions in real-world settings.

To spur innovation to meet the challenges of complex care management for people with Alzheimer’s disease and related dementias (AD/ADRD) and their families, the National Institute on Aging (NIA), part of the National Institutes of Health, has funded a new effort designed to test care interventions in real-world settings.  Brown University, Providence, Rhode Island, will partner with Hebrew Senior Life, a Harvard Medical School Affiliate, Roslindale, Massachusetts, to manage the Imbedded Pragmatic AD/ADRD Clinical Trials (IMPACT) Collaboratory with funding from NIA that is expected to total $53.4 million over five years. IMPACT Collaboratory researchers will team with scientists at other universities with health care and long-term care systems to guide research to develop and test novel ways to care for people with AD/ADRD.

Methotrexate and the more expensive mycophenolate mofetil performed similarly in a head-to-head clinical trial that compared the two drugs for treating noninfectious uveitis, an eye disease that accounts for up to 15% of blindness in the U. S. In cases of more severe disease, posterior uveitis and panuveitis, the international trial showed that methotrexate was more effective in controlling inflammation.

Methotrexate and the more expensive mycophenolate mofetil performed similarly in a head-to-head clinical trial that compared the two drugs for treating noninfectious uveitis, an eye disease that accounts for up to 15% of blindness in the U. S. In cases of more severe disease, posterior uveitis and panuveitis, the international trial showed that methotrexate was more effective in controlling inflammation. Investigators published results from the trial today in the Journal of the American Medical Association. The National Eye Institute, part of the National Institutes of Health, funded the trial.

Eminence Business Media’s “Pharma Brand Protection & Packaging 2019” concluded on August 29 th  & 30 th , 2019 at Hotel Novotel, Mumbai.The theme of the summit was “Trends that have revolutionized the Pharma Packaging World”.The event was an outstanding success with 150+ delegates attending the conference with Karomi Technologies, Autoprint Machinery Manufacturers Pvt. Ltd, Condot Systems, Original 4 Sure, Great Four Systems Pvt. Ltd., Bobst India, Novel Automation Ltd., Bullion Flexipack Pvt. Ltd, Pharma Secure, Aptar Pharma, Nipro Pharma Packaging, Systech International, Immer Group, Sun Packaging, Nuplas Industries, Pharma Mantra, GS1 India, PCRI & ASPA partnering the event.